Welcome to the Department of Hematology, Oncology, and Rheumatology at Heidelberg University Hospital
At the Department of Hematology, Oncology, and Rheumatology, patients with hematologic or oncological diseases such as lymphoma, chronic lymphocytic leukemia (CLL), multiple myeloma, and acute leukemia receive optimal, state-of-the-art medical care.
Guided by our key principle, “healing through competence and cutting-edge research”, we work continuously to make new therapies and drugs available to our patients as soon as possible. Our physicians and scientists are therefore actively and successfully involved in top-level international medical research on leukemia, lymphoma, and myeloma, often heading their research teams.
Our core expertise is in cell therapies using bone marrow and blood stem cell transplants. In 1983, a stem cell transplant unit was opened in the Department of Hematology, Oncology, and Rheumatology. Since 1997, we have been performing autologous stem cell transplants with cells taken from the patient as well as allogeneic transplants with cells from related or unrelated donors. We now perform more than 200 autologous and close to 100 allogeneic transplants annually. This makes us one of the largest stem cell transplant centers in Germany. Our many years of experience in this area allow us to determine the optimal treatment for each patient.
Our focus is on treating the following diseases:
- Leukemia (acute and chronic myeloid and lymphocytic leukemia, hairy cell leukemia).
- Lymphoma (e.g., Hodgkin’s and non-Hodgkin’s lymphoma).
- Multiple myeloma.
- Other hematologic diseases, such as aplastic anemia, thrombocythemia, hemoglobinopathies, and hemolytic anemia.
Every year, our teams of specialists treat approximately 270 new leukemia patients, 210 lymphoma patients, and 280 new patients with multiple myeloma. The average length of stay is 12.5 days. Moreover, we offer many of our patients the opportunity to participate in our own clinical studies.
In addition to offering bone marrow and blood stem cell transplants, we also treat leukemia and cancer patients with chemotherapy and immunotherapy as well as with immune cell therapy.
We also work cooperatively with the departments of Radiation Therapy and Nuclear Medicine, with the German Cancer Research Center (DKFZ,) and with the National Center for Tumor Diseases in Heidelberg (NCT) to offer both classic radiation and new treatment forms such as radioimmunotherapy and tumor vaccination. We discuss all cases in a regular interdisciplinary conference in order to develop a customized treatment plan.
We have our own coordination unit that conducts the search for and harvesting of stem cells from related and unrelated donors. The team also conducts international donor searches in the “Collection Center”, and we have been able to find suitable donors for almost all of our patients.
Other areas of activity are the morphological, immunological, and genetic diagnosis of leukemia and lymphoma in our special laboratory and individualized guidance for patients with chronic lymphocytic leukemia, lymphoma, or multiple myeloma.
Our outstanding technical facilities include our own bone marrow and blood stem cell transplant unit with a total of ten beds for our transplant patients and the GMP laboratory, operated jointly with Cytonet. In this laboratory, bone marrow and blood stem cell products and immunocompetent cells are processed using what are known as “good manufacturing practice” (GMP) criteria.
Wishing you a quick recovery,
Professor Dr. Carsten Müller-Tidow
Medical Director of the Department of Hematology, Oncology, and Rheumatology at Heidelberg University Hospital